Clinical Trials Browser

Phase 2 × INDUSTRY × naquotinib × Clear all

NCT02500927 2024-11-20

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT03042013 2017-07-11

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms